Claims for Patent: 8,741,338
✉ Email this page to a colleague
Summary for Patent: 8,741,338
Title: | Targeted delivery to human diseases and disorders |
Abstract: | The present invention provides a system presenting site-specific accumulation through a ligand that specifically targets a receptor overexpressed on the surface of specific cells within a target organ, like, for example, tumor cells and/or vascular cells of tumor blood vessels. Moreover, this invention provides a method where, upon internalization of the previous-mentioned system by the target cells, triggered release at a high rate of the associated agent takes place, permitting efficient intracellular delivery and, thus, increased concentration of the transported cargo at the target site. Overall, this invention provides a method for the diagnosis, prevention and treatment of human diseases and disorders. |
Inventor(s): | de Almeida Moreira; Joao Nuno Sereno (Coimbra, PT), Caldeira de Moura; Vera L cia Dantas Nunes (Coimbra, PT), de Magalhaes Simoes; Sergio Paulo (Coimbra, PT), Pedroso de Lima; Maria da Conceicao Monteiro (Coimbra, PT) |
Assignee: | Universidade de Comibra (Coimbra, PT) Centro de Neurociencias e Biologia Celular (Coimbra, PT) |
Application Number: | 14/020,592 |
Patent Claims: | 1. A method of delivering an agent to a cell of a tumor or tumor vasculature, the cell expressing nucleolin, comprising administering to a subject having the cell expressing
nucleolin a ligand-targeted delivery system, wherein the ligand-targeted delivery system is a targeting ligand linked to a support carrying an agent, wherein said targeting ligand binds nucleolin, wherein said support is a pH sensitive liposome, wherein
the agent is a therapeutic, diagnostic and/or imaging agent, encapsulated, entrapped or intercalated in the support, and wherein said liposome is capable of the pH dependent intracellular release of said agent.
2. The method of claim 1, wherein the administration is intravenous administration. 3. The method of claim 1, wherein said targeting ligand is a peptide comprising the amino acid sequence of SEQ ID NO:1. 4. The method of claim 1, wherein a spacer is positioned between the ligand and the support such that the interaction of the ligand with the target is not hindered. 5. The method of claim 1, wherein the liposome comprises fully hydrogenated soy phosphatidylcholine, methoxy-polyethylene glycol phosphatidylethanolamine, maleimide-polyethylene glycol phosphatidylethanolamine, N-methylpalmitoyloleoylphosphatidylcholine, phosphatidylserine, phosphatidylcholine, palmitoyloleoylphosphatidylcholine, dipalmitoylphosphatidylcholine, distearoylphosphatidylcholine, phosphatidylglycerol, dioleoylphosphatidylethanolamine, cholesteryl hemisuccinate, cholesterol, or a combination thereof. 6. The method of claim 1 wherein the agent is a cytotoxic, an anti-cancer, anti-inflammatory, an anti-angiogenic, an angiolytic, a vascular disrupting agent or a photodynamic therapeutic agent. 7. The method of claim 1, wherein the agent comprises alkylating drugs; cytotoxic antibiotics; antimetabolites; vinca alkaloids; amsacrine; altetarmine; crisantaspase; dacarbazine; temozolomide; hydroxycarbamide (hydroxyurea); pentostatin; platinum compounds; porfimer sodium; procarbazine; razoxane; taxanes; topoisomerase I inhibitors; trastuzumab; tretinoin; SN-38; ET-743; TLK 286; anti-inflammatory agents; antiangiogenic agents or angiolytic agents; ABT-627; Bay 12-9566; Benefin; Bevacizumab; BMS-275291; cartilage-derived inhibitor (CDI); CAI; CD59 complement fragment; CEP-7055; Col 3; Combretastatin A-4; Endostatin (collagenXVIII fragment); Fibronectin fragment; Gro-beta; Halofuginone; Heparinases; Heparin hexasaccharide fragment; HMV833; Human chorionic gonadotropin (hCG); IM-862; Interferon alpha/beta/gamma; Interferon inducible protein (IP-10); Interleukin-12; Kringle 5 (plasminogen fragment); Marimastat; Metalloproteinase inhibitors (TIMPs); 2-Methoxyestradiol; MMI 270 (CGS 27023A); MoAbIMC-1C11; Neovastat; NM-3; Panzem; PI-88; Placental ribonuclease inhibitor; Plasminogen activator inhibitor; Platelet factor-4 (PF4); Prinomastat; Prolactin 16 kD fragment; Proliferin-related protein (PRP); PTK 787/ZK 222594; Retinoids; Solimastat; Squalamine; SS 3304; SU 5416; SU6668; SU11248; Tetrahydrocortisol-S; tetrathiomolybdate; thalidomide; Thrombospondin-1 (TSP-1); TNP-470; Transforming growth factor-beta (TGF-b); Vasculostatin; Vasostatin (calreticulin fragment); ZD6126; ZD 6474; farnesyl transferase inhibitors (FTI); bisphosphonates; or porphyrins. 8. The method of claim 1, wherein the pH sensitive liposome destabilizes in an acidic environment. 9. The method of claim 1, wherein the pH sensitive liposome destabilizes in the endosome compartment of the cancer cell. 10. The method of claim 1, wherein the agent comprises a radionuclide or a fluorescent molecule. 11. The method of claim 1, wherein the agent comprises cyclophosphamide, chlorambucil, melphalan, busulfan, lomustine, carmustine, chlormethine (mustine), estramustine, treosulfan, thiotepa, and mitobronitol. 12. The method of claim 1, wherein the agent comprises doxorubicin, epirubicin, aclarubicin, idarubicin, daunorubicin, mitoxantrone (mitozantrone), bleomycin, dactinomycin or mitomycin. 13. The method of claim 1, wherein the agent comprises methotrexate, capecitabine, cytarabine, fludarabine, cladribine, gemcitabine, fluorouracil, raltitrexed (tomudex), mercaptopurine, tegafur or tioguaninc. 14. The method of claim 1, wherein the agent comprises vinblastine, vincristine, vindesine, vinorelbine or etoposide. 15. The method of claim 1, wherein the agent comprises carboplatin, cisplatin or oxaliplatin. 16. The method of claim 1, wherein the agent comprises docetaxel or paclitaxel. 17. The method of claim 1, wherein the agent comprises inotecan or topotecan. 18. The method of claim 1, wherein the agent comprises ibuprofen, aceclofenac, acemetacin, azapropazone, celecoxib, dexketoprofen, diclofenac sodium, diflunisal, cetodolac, fenbufen, fenoprofen, flubiprofen, indomethacin, acetaminocin, piroxicam, rofecoxib, sulindac, tenoxicam, tiaprofenuic acid, aspirin or benorilate. 19. The method of claim 1, wherein the agent comprises Angiostatin (plasminogen fragment), antiangiogenic antithrombin III or Angiozyme. |
Details for Patent 8,741,338
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.